HSTO News and Press, Histogen Inc. From 01/07/21

DLA Piper advises Histogen in its US$14 million upsized public offering PR Newswire NEW YORK , Jan. 7, 2021 /PRNewswire/ -- DLA Piper represented advised Histogen, Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potentia...

SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today an...

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that...

Gainers: Hoth Therapeutics (HOTH) +49%. Bionano Genomics (BNGO) +38%. Clearside Biomedical (CLSD) +17%. Regional Health Properties (RHE) +14%. Ampio Pharmaceuticals (AMPE) +13%.Losers: Histogen (HSTO) -26%. Novan (NOVN) -22%. ORIC Pharmaceuticals (ORIC) -14%. DermTech (DMTK) -12%. T...

Histogen (HSTO) priced a public offering of 14M shares along with accompanying warrants at an effective public offering price of $1.00/share.Warrants have an exercise price of $1.00/share, are immediately exercisable, and expire five years following issuance date.Gross proceeds...

SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that...

uniQure (QURE) -18% after the FDA clinical hold on its hemophilia B gene therapy program, including the pivotal, Phase 3 HOPE-B study.MingZhu Logistics Holdings Limited (YGMZ) -11%.CYREN (CYRN) -13%.Transocean (RIG) -11%.The9 (NCTY) -11%.DBV Technologies (DBVT) -11%.FibroG...

Histogen ([[HSTO]] -4.0%) has submitted an Investigational New Drug ((IND)) application with the FDA for the initiation of a Phase 1/2 trial to evaluate HST-003, extracellular matrix.The study will assess the safety and efficacy of human  implanted within microfracture int...

Phase 1/2 Trial Initiation for Knee Cartilage Regeneration Anticipated in First Quarter 2021 $2M Grant Awarded by the Department of Defense in September 2020 to Support Clinical Development SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical...

Micro-cap Histogen ([[HSTO]] +173.4%) after announcing preliminary week 18 results from its Phase 1b/2a trial evaluating HST-001 in androgenic alopecia (male pattern baldness).At the week 18 primary efficacy endpoint, patients treated with HST-001 demonstrated separation from placebo for...